Demodex Blepharitis in Scleral Lens Wearers
ConditionDemodex Blepharitis
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorBoston Sight
About this trial
The purpose of this study will be to see if Xdemvy (lotilaner ophthalmic solution) 0.25% has a positive impact on ocular surface symptoms and PROSE device functionality and performance.
The investigators hypothesize the use of Xdemvy in subjects utilizing PROSE treatment will be well tolerated and that the reduction in Demodex mite load on the eyelid margin will result in reduced ocular surface symptoms and improved PROSE tolerance and functionality.
Eligibility criteria
Qualifiers
Written Informed Consent has been obtained prior to any study-related procedures taking place
Subject is Male or Female, 18 years of age or older prior to the initial visit
Is an established wearer of PROSE devices for > 6 months in both eyes
Currently wears PROSE devices on a daily basis in both eyes
Disqualifiers
Is currently participating in any other type of eye-related clinical research study
Is pregnant or nursing as reported by the subject.
Has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study.
Has had previous ocular surgery within the past 12 weeks or has planned ocular surgery during the study period.
Trial design
Treatments tested in this trial
- Xdemvy
Treatment groups
5 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov